TIP767: Mastermind Discussion Q4 2025: Sanofi, Remitly & Crocs w/ Stig Brodersen, Tobias Carlisle, and Hari Ramachandra

You're listening to TIP. In today's mastermind discussion, we're diving into three different businesses, each with its own story and set of opportunities. Hari will be pitching Sanofi, a global pharmaceutical leader with a promising pipeline in vaccines and immunology. I will be sharing my thoughts on Remedy, a fast growing digital remittance company, helping millions of people send money across borders more efficiently. And Toby's pick is Crocs. The footwear brand has gone from fashion punchline to global powerhouse, yet still appears quite cheap. This mastermind format is all about testing our ideas, asking the hard questions, and exploring where we might be wrong. Over the years, I found it not only makes me a better investor, but also keeps me grounded and curious, and I hope it does the same for you. Towards the end of the episode, my co host Clay and I will also talk about what's next for our Mastermind community, including our plans for live events in Omaha and New York City, and how you can join us. Since 2014 and through more than 180,000,000 downloads, we've studied the financial markets and read the books that influence self made billionaires the most. We keep you informed and prepared for the unexpected. Now for your host, Stake Brodersen. Welcome to The Investors Podcast. I'm your host, Stig Brodersen. And today, I'm here with Hari and Toby. Jens, how are you today? What's up, Stig? Good to see you again. Hey, Harry. How are you? Hey, what's up, Toby and Stig? Good to see you. Fantastic. And let's just jump right into the first pick. Hari, we talked about it just before we hit record and you volunteered. So let me throw it back over to you. What is your pick? Zappia (zero zero three:thirty seven): Thank you, Jake. And no pressure going first, but I've been looking into stocks that are undervalued and it's not easy in this current market. But today I have another pharmaceutical pick, Sanofi. It's a global biopharma focused on immunology and vaccines. It's based in Europe, France, and it's well known across the globe. And I think of this company having two engines. The first one is their anti inflammatory blockbuster drug Dupixent, which has got approval across multiple indications, including COPD and has a decade long runway to go before patent expires. And the second engine is their vaccines. Of course, I'm simplifying it. They have much more apart from this. But they are really well known for their vaccine, including the seasonal flu, infant RSV protection, and many other really high quality vaccines. And since I have a lot of experience in SaaS, software as a service business, I see vaccines very similar to software as a service. It's a subscription model because it's something that everybody takes during the flu season. It's kind of a repeat business for them. So it's a recurring revenue. So vaccine is really their core strength and a stable source of income …